Trial TCTR20210907003, TCTR20211102006
Publication Niyomnaitham S, Vaccines, 2022
Primary outcome on the report: anti-RBD SARS-CoV-2 IgG antibody geometric mean concentrations (GMC) two weeks after vaccine injection

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.